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Abstract
Background and purpose: 3-dimensional conformal therapy (3DCRT) is widely employed radiation therapy technique for breast
cancer, but there is still need to minimize the doses to organ at risk (OAR) using 3DCRT. A few clinical studies have discussed
using intensity modulated radiation therapy (IMRT) to address this shortfall. Simultaneous integrated boost (SIB) has been used
in head and neck and prostate cancer, and there is a growing interest in using SIB for breast cancer too. This study aimed to
compare SIB-IMRT versus SIB-3DCRT for breast cancer patients. Materials and Methods: SIB-3DCRT treatment plans were
created for 36 consecutive patients. Dose was prescribed as 45 Gy in 25 fractions to the planning target volume (PTV)-1 and 60
Gy in 25 fractions to PTV-2. Treatment plans were normalized to 95% of PTV volume receiving 95% of the prescription dose.
The conformity index (CI), homogeneity index (HI), lung dose, heart dose, left anterior descending artery(LAD) dose, and low
dose volume and integral dose of normal healthy tissue were recorded and analyzed. Results: With the use of IMRT technique,
there was an improvement in CI (0.14) when compared to CI of 3DCRT (0.18; p = 0.01). However, there was no significant dif-
ference in the HI (p = 0.45). On average, the V20Gy of ipsilateral lung was 37.9 % for 3DCRT and 22.4 % (p < 0.01) for IMRT,
whereas the V20Gy of total lung (ipsilateral + contralateral) was 21.8% for 3DCRT and 12.14 (p < 0.01) for IMRT. Similarly, aver-
age V40Gy of heart was 7.5 % for 3DCRT and 2.13 % (p = 0.01) for IMRT. The LAD maximum dose to left side breast patients, on
average, was 39.5 Gy for 3DCRT and 29.17 Gy (p = 0.03) for IMRT. The average number of monitor units was about 180 for
3DCRT and 1441 (p < 0.01) for IMRT. Conclusion: IMRT for breast cancer treatment is feasible. In comparison to 3DCRT,
IMRT can reduce the maximum dose to the target volume, and dose to the OAR. However, 3DCRT technique is superior in
terms of low dose volume, integral dose, and treatment time. With the use of breath-hold gated technique in IMRT, it can fur-
ther improve the target coverage and reduction of doses to the heart, lung, and LAD. SIB technique could reduce the overall
treatment duration by about one week.
Keywords: Intensity Modulated Radiation Therapy, Three Dimensional Conformal Radiotherapy, Simultaneous Integrated
Boost, Breath-Hold, Technique, Breast Cancer
Introduction
Breast cancer is the most common malignancy in women.
Radiotherapy is an integral part of breast cancer manage-
ment either in breast conservation surgery (BCS) or in post
mastectomy cases. Many prospective studies have shown
that adjuvant radiotherapy improves local control and sur-
vival rate in breast cancer patients after surgery.1 During
earlier days of radiotherapy, opposed wedged fields with half
beam block was considered as the standard radiation therapy
technique. In the last decade, an introduction of linear ac-
celerators has made 3-dimensional conformal radiotherapy
(3DCRT) as a standard treatment technique, which can
re-duce the doses to the lung, heart, and other critical struc-
ture doses in the breast cancer treatment. However, using
3DCRT, it is not always possible to achieve adequate normal
tissue sparing, especially when treating left side chest wall
patients. This is mainly due to overlying concave shape of
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the target, which can result more doses to adjacent structures
such as heart and lung. Hong et al.2 compared intensity
modulated radiation therapy (IMRT) with 3D conformal
tangential wedged beams, and showed the reduction of dose
to the coronary arteries, contra lateral breast, ipsilateral lung,
and surrounding soft tissues using IMRT. By modulating
photon beam, it is possible to obtain concave and convex
shape dose distributions with IMRT, and it has the ability to
conform radiation dose to irregular target volumes sparing
the underlying critical structures resulting in better tumor
control probability (TCP) and reduced normal tissue com-
plication probability (NTCP). The main purpose of this study
was to further evaluate normal tissue sparing and dosimetric
analysis of simultaneous integrated boost (SIB)-3DCRT and
SIB-IMRT in breast patients, with focus on breath-hold gat-
ed technique.
Materials and Methods
In this retrospective treatment planning study, we used
computed tomography (CT) data of 36 consecutive patients
with breast cancer post lumpectomy (18 left sides and 18
right sides), and all patients were treated with respiratory
gated technique for breast radiotherapy.
CT Simulation
All 36 patients were simulated using 4D CT scanner (Philips
Medical Systems, Andover, MA, USA) with whole-body
Vaclok (Civco Medical Solutions, Iowa, USA) immobilization
system. Patients were positioned on a wide bore CT-SIM
couch with the help of lasers, and both arms of the patient
were raised above patient’s head. Furthermore, radio opaque
markers were placed during the immobilization procedure to
guide the isocenter shift. For all the patients, CT scans imag-
es were obtained from mandible to upper abdomen area with
intravenous contrast, and CT scans were obtained using slice
thickness of 5 mm. Prior to CT simulation, patients were
given training on breath-hold technique.
Target Delineation and Dose Prescription
After the CT simulation, the Digital Imaging and Communi-
cations in Medicine (DICOM) images were transferred to
Eclipse treatment planning system (TPS) (version 10.0.34,
Varian Medical Systems, Palo Alto, California, USA). Clinical
target volume (CTV), planning target volume (PTV) and
Organ at Risk (OAR) volumes were delineated on the axial
CT slices. The lumpectomy gross tumor volume (L-GTV) was
contoured using all available clinical and radiographic in-
formation including the excision cavity volume, architectur-
al distortion, lumpectomy scar, seroma and/or extent of sur-
gical clips.
CTV1 included the palpable breast tissue demarcated with
radio opaque markers at CT simulation. The apparent CT
glandular breast tissue visualized by CT, consensus defini-
tions of anatomical borders, and the lumpectomy CTV from
the RTOG breast cancer atlas. The breast CTV is limited
anteriorly within 3 mm from the skin and posteriorly to the
anterior surface of the pectoralis, serratous anterior muscle
excluding chest wall. PTV was created by 3D expansion of
CTV1 by 7 mm. CTV2 was created by 1 cm 3D expansion
from L-GTV and was limited posteriorly at anterior surface
of the pectoralis and antero-laterally 3 mm from skin. PTV2
was created by 7 mm 3D expansion of CTV2. The normal
structures were contoured as ipsilateral lung, contra lateral
lung, contra lateral breast, heart, left anterior descending
(LAD) artery, spinal cord, esophagus, trachea, humerus head,
and liver. Dose prescription was applied per International
Commission on Radiological Units and Measurements
(ICRU) 50 and 62.3, 4 Specifically, dose was prescribed as 45
Gy in 25 fractions (1.8Gy/fraction) to the PTV-1 and 60 Gy
in 25 fractions (2.4Gy/fraction) to PTV-2.
Treatment planning
For treatment planning, 6 mega-voltage (MV) X-rays from
Clinac 600CD linear accelerator (Varian Medical Systems,
Palo Alto, California, USA) integrated with 120 leaves mil-
lennium multi-leaf collimator (MLC) was used. For the dy-
namic IMRT plans, 7 non-coplanar beams were used to
achieve the minimum criteria of 95% of the volume received
95% of the prescribed dose. The treatment fields were almost
evenly spaced within an arc of 1800 on the side of the tumor.
Gantry angles ranged from 3300 to 1500 (clockwise) for the
left side tumors and from 500 to 2100 (counterclockwise) for
the right side tumors. In Eclipse TPS, the IMRT plans were
created with inverse plan optimization, and the algorithm
used was Dose Volume Optimizer (version 10.0.28). For the
dose calculation, pencil beam convolution (PBC) algorithm
(version 10.0.28) was used, and leaf motions were calculated
with leaf motion calculator (LMC) algorithm (version
10.0.28). Heterogeneity correction was done using modified
Batho method in the Eclipse. For plan optimization, OAR
dose constraints were given as ipsilateral lung V20 < 30 %,
heart V30, V40, and mean dose as low as possible, con-
tra-lateral breast mean dose less than 5 Gy, and spinal cord
maximum point dose less than 40 Gy. For the 3DCRT
plans, 4 to 6 non-coplanar beams were used to produce ade-
quate dose coverage for the PTV. Critical organs were
shielded using MLC without compromising PTV coverage.
Beam weights were adjusted until the optimum coverage and
acceptable hot spots were achieved. Additionally,
field-in-field was created to reduce hotspot equal to or lower
than 110% as well as to improve the target coverage and
homogenous dose distribution in the PTV.
Plan evaluation
Dose-Volume Histograms (DVH) was used to analyze the
volume receiving 20 Gy, 30 Gy and 40 Gy, mean, maximum
and minimum doses. The target dose uniformity and con-
formity were calculated and evaluated. Different scoring
indices were given by various authors.5-7 In this study, we
have followed indices defined by ICRU 83. 8
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The conformity index (CI) as defined in ICRU 83 is
ref
Volume of PTV covered by the reference dose
CI = Eq. 1
Volume of PTV
CI = 1.0 is ideal value
The Homogeneity Index (HI) as defined in ICRU 83 is







Where, D 2%, D 98%, D 50% is dose received by 2%, 98%, 50%
volume. HI = 0 (Zero) is ideal value. Also, to illustrate the
low dose volume effect, V5Gy volume and integral dose were
calculated for normal healthy tissue.
Integral Dose = Mean Dose (Gy) × Volume (Cm3) Eq. 3
Statistical Analysis
Statistical Analysis was performed using the Wilcoxon
Signed Rank test. This matched pair t test was applied to
determine the statistical difference between the
dose–volume data for IMRT versus 3DCRT. The values are
reported in ranges. The reported p value is two tailed, and p
values of < 0.05 are considered statistically significant.
Results and Discussion
Dose volume histograms of the normal tissues of both the
plans (IMRT and 3DCRT) are presented in Table 1. The
normalized target coverage of both treatment methods is
presented in Table 2 and Table 4. The PTV mean dose for
3DCRT is 47.10 Gy compared to 45.88 Gy (p < 0.01) with
IMRT. The dose distribution in axial sections is shown in
Figures 1 and 2. These axial sections clearly show that con-
cave PTV coverage and exclusion of LAD during optimiza-
tion by IMRT. Also, previous studies have reported lower
doses to the ipsilateral lung, contra lateral lung, contra lateral
breast, heart, and LAD doses using IMRT technique.10, 11
3D conformal plans using asymmetric jaw and field-in-field
technique provides better coverage than a conventional
physical wedged –half beam blocked or physical
wedged-asymmetric fields. Furthermore, physical wedge has
limitation in field width and lengths. With 3DCRT, the hot
spots occurred in superficial skin surface, but IMRT exhibit-
ed better control in shifting the hot spots, with a possibility
of keeping dose to the skin equal to or less than the prescrip-
tion dose.
Dose homogeneity and conformity
The use of equally spaced gantry angles improved homoge-
neity and conformity indices as well as reduced the volume
of critical normal tissues such as the heart and ipsilateral
lung receiving a high dose as shown by Hong et al. 2. In this
study, we used equally spaced beam angles for both the
IMRT and 3DCRT plans, and the average target maximum
dose was lower with IMRT; however, it was not statistically
significant. Although the mean breast volume in our study
was 1221 cc, which is relatively higher compared to the lit-
erature 12, we were able to demonstrate optimized coverage
and reduced dose to the critical organs.
The inverse-planning IMRT further reduced hotspots mainly
due to beam modulation during optimization compared to
3DCRT, where beam modulation is not available. Previous
planning studies13,14 with multiple fields showed the
PTV-95% coverage values ranging from 90% to 97 %,
whereas all our optimized plans had the PTV-95% coverage
values of >95% of prescription dose. With the use of IMRT
technique, our data showed that there is a consistent im-
provement in conformity index from 0.18 for 3DCRT to 0.15
for IMRT (p=0.01). However, there was no significant dif-
ference (p = 0.45) when HI of 3DCRT was compared to that
of IMRT.
TABLE 1: Comparison of normal tissue dose volume parameters for
Respiratory Gated IMRT and 3DCRT  breast cancer patients (Statis-
tics based on Wilcoxon Signed Rank Test). The values are averaged
over 36 analyzed patients.
Organ Parameter SIB-3DCRT SIB-IMRT
Ipsilateral lung
V20Gy (%) 37.9 22.4
V30Gy (%) 32.24 16.08
Mean (Gy) 20.29 16.51
Heart V40Gy (%) 7.5 2.13
Both Lung V20Gy (%) 21.8 12.14
LAD Max. Dose (Gy) 39.5 29.17
TABLE 2: Comparison of planning target volume (PTV1) coverage
parameter for Respiratory Gated IMRT and 3DCRT breast cancer
patients (Statistics based on Wilcoxon Signed Rank Test). The values
are averaged over 36 analyzed patients.
PTV 1 Parameter SIB-3DCRT SIB-IMRT p
Minimum Dose (Gy) 24.07 32.03 <0.01
Maximum Dose (Gy) 51.97 59.68 <0.01
Coverage (%) 96.8 98.22 <0.01
Conformity Index 0.18 0.14 0.01
Homogeneity Index 1.03 1.01 0.45
Mean Dose (Gy) 47.1 45.88 <0.01
Mod Dose (Gy) 49.12 48.92 0.32
Median Dose (Gy) 50.5 48.8 <0.01
Stnd. Deviation(Gy) 6.35 4.17 <0.01
V50Gy (%) 48.69 29.83 <0.01
V55Gy (%) 30.7 11.29 <0.01
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FIG. 1: Axial slice showing dose distribution in 3DCRT plan. The
3DCRT was unable to exclude LAD while covering the concave
target, and increased dose to the heart and lung was noticed.
TABLE 3: Comparison of MU, ID and V5 parameter for Respiratory
Gated IMRT and 3DCRT breast cancer patients (Statistics based on
Wilcoxon Signed Rank Test). The values are averaged over 36 ana-
lyzed patients.
Parameter SIB-3DCRT SIB-IMRT p
Monitor Units 180 1441 <0.01
Integral Dose (Gy-Cm3) 145210 197428 <0.01
V5Gy (%) 18.89 30.61 <0.01
TABLE 4: Comparison of planning target volume (PTV2) coverage
parameter for Respiratory Gated IMRT and 3DCRT breast cancer
patients (Statistics based on Wilcoxon Signed Rank Test). The values
are averaged over 36 analyzed patients.
PTV 2 Parameter SIB-3DCRT SIB-IMRT p
Minimum Dose (Gy) 56.41 53.9 <0.01
Maximum Dose (Gy) 64.9 64.01 <0.01
Coverage (%) 98.3 99.77 0.13
Conformity Index 0.12 0.08 0.01
Homogeneity Index 1.02 1.01 0.11
Mean Dose (Gy) 61.1 61.72 0.13
Mod Dose (Gy) 61.17 62.13 <0.01
Median Dose (Gy) 61.99 62.45 <0.01
Stnd. Deviation(Gy) 1.5 1.21 0.01
TABLE 5: Comparison of Non-Gated IMRT with respiratory Gated
IMRT (mean) breast cancer patients (Statistics based on Wilcoxon






LAD-Maximum Dose 35.62 Gy 29.17 Gy <0.01
Heart -V30Gy 9.27 % 5.91 % <0.01
Ipsilateral Lung-V20Gy 30.2 % 22.4 % 0.03
PTV -95% of prescription 96.81% 98.22 % <0.01
In patients with breast cancer, it is intended that the irradi-
ated heart volume be minimized to the greatest possible de-
gree without compromising the target coverage. The risk of
pericardial events is probably related to both dose and vol-
FIG. 2: Axial slice showing dose distribution in IMRT plan. The
IMRT was able to exclude LAD while covering the concave target,
and decreased dose to the heart and lung was noticed.
ume of radiation. The incidences of pericardial disease de-
crease with the use of sub cranial blocking the major ventri-
cles at 30 Gy. Stewart et al. 15 concluded that the dose should
be limited to 60 Gy for less than 25% of cardiac volume and
45 Gy for more than 65% of cardiac volume.
In patients with breast cancer, it is intended that the irradi-
ated heart volume be minimized to the greatest possible de-
gree without compromising the target coverage. The risk of
pericardial events is probably related to both dose and vol-
ume of radiation. The incidences of pericardial disease de-
crease with the use of sub cranial blocking the major ventri-
cles at 30 Gy. Stewart et al. 15 concluded that the dose should
be limited to 60 Gy for less than 25% of cardiac volume and
45 Gy for more than 65% of cardiac volume.
In our study the heart V40Gy was significantly lower in IMRT
than in 3DCRT (p < 0.01), especially for left sided breast
cancer patients, with mean heart V40 Gy of 7.5% for 3DCRT
versus IMRT as 2.13% (p = 0.01). Gagliardi et al.16 reported
that CAD risk was much reduced at doses less than 30 Gy.
Mean values of V30Gy were <5% for IMRT compared with
studies17 reporting V30Gy values in the range of 2% to 5%.
Increased cardiac mortality risk associated with left side
breast patients in the long term was reported by multiple
authors.16, 18, 19 The advancement in treatment techniques
such as IMRT has enabled to reduce cardiac exposure, and
steady decline of radiation risk is being noticed.20 Further-
more, Boivin et al.21 noted that the anteriorly placed coro-
nary arteries were more often affected by radiation therapy
(compared with the circumflex artery). In our study, mean
LAD maximum dose was 39.5 Gy for 3DCRT and 29.17 Gy
for IMRT (p = 0.03).
Lung dose
The occurrence of radiation pneumonitis (RP) is related to
the ipsilateral lung volume irradiated.22 In our study, the
ipsilateral lung V20Gy for IMRT (22.4%) is significantly less
than that for 3DCRT (37.9%; p < 0.01). Ipsilateral lung mean
dose was also higher in 3DCRT (20.29 Gy) compared to the
one in IMRT (16.51Gy) (p < 0.01). Both the lung V20Gy and
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mean dose were significantly lower in IMRT than in 3DCRT
(p < 0.01). Contra lateral lung V5Gy and mean dose of both
the plans showed no significant differences. The mean lung
doses (MLD) of both lung were higher compared to the re-
port from Marks et al.23, and this may be due to larger breast
volumes in our study. Since there is no absolute safe MLD
below which there is no pneumonitis, the clinically accepta-
ble risk of RP depends on the risk-benefit ratio of the indi-
vidual patient selection basis.
Secondary malignancy
The IMRT plans contributed a modestly higher dose to adja-
cent healthy soft tissues. In our study, the mean V5Gy volume
for 3DCRT was much lower than that of IMRT. The main
concern with healthy tissue dose increases of this magnitude
is an increased risk of late second malignancy.24, 25 Some in-
vestigators suggest that IMRT might increase the incidence
of secondary cancer from 1% in conventional planning to
1.75% in IMRT planning for patient’s surviving 10 years.24
Furthermore, the treatment Monitor Unit (MU) was signifi-
cantly higher in IMRT technique. The monitor unit for
IMRT is 6-8 times more than 3DCRT is a concern.24, 26, 27 This
in turn shows that the integral dose would be higher.
Pirzkall et al. 28 studied that the integral dose for IMRT was
higher than conventional treatment. Similar observation was
made in our study as integral dose for IMRT was 22% higher
than that for 3DCRT. This higher integral dose was probably
due to increased number of beams used in IMRT than in 3D
CRT, thus involving larger volume of healthy tissue during
IMRT plan optimization. Modulation of beams also increases
the treatment time during treatment delivery. Furthermore,
the leakage and scatter dose to non-target tissue of the pa-
tients will be proportional to the number of monitor units
used. Few studies 13, 29 have found to have increased low dose
volumes with increasing beam angles.
High integral dose attributed to second malignancy, which is
likely to be of greatest concern in younger women and in
patients with a low risk for systemic relapse that are likely to
live for many years after the diagnosis of breast cancer.27
There have been reports24 suggesting that adjuvant radiation
therapy for breast cancer may increase the risk of lung can-
cer and angiosarcoma. The risk of sarcoma in the treated
volume is likely to be similar with IMRT or standard tech-
niques, but it is possible that second primary lung cancers
might be increased by IMRT, especially if the woman is a
smoker.27 Therefore, individual assessment of treatment
volume goals and longevity of patients with and without
radiation therapy is necessary in order to balance the short
to medium-term benefits of reducing the volume of critical
structures, especially heart and lung, receiving higher radia-
tion dose.
Respiratory gating
Organ motion during the IMRT treatment has been ac-
counted for using real-time position management (RPM;
Varian Medical System, Palo Alto, California, USA). The
RPM system supports automatic on and off triggering of ra-
diation beam during the treatment. The marker position
approximates identical and in-phase alignment of breast and
marker motion. Due to breathing motion, the PTV may
move outside the external contour as defined on the plan-
ning CT and result in a geographic miss of the target. Alt-
hough the geometric uncertainties and intra fraction move-
ment are taken into account on PTV margin, but the breast
is a superficial organ and often the CTV will extend to the
skin surface. In these cases, the restriction of the PTV to 3
mm from the skin surface will not provide an adequate mar-
gin for intra-fraction breathing motion.29-33 The main con-
cern would be the CTV being under-dosed. In order to use
gating, the PTV motion must be in phase with the breathing
cycle or must at least be able to be predicted from the
breathing cycle using technology such as RPM. Conformal
blocking and breath-hold techniques can essentially elimi-
nate the heart from the primary beams. Historically, whole
heart doses up to 30 Gy were reasonably well tolerated. 34-36
Conclusion
IMRT for breast cancer treatment is feasible. In comparison
to 3DCRT, IMRT reduced the maximum dose to the target
volume, and dose to OAR was reduced too. However,
3DCRT technique was superior in terms of low dose volume
of normal tissue, integral dose, and treatment time. Conse-
quences of these low doses would have to be weighed against
the benefits of reducing high doses on individual patient
selection basis. With the use of breath-hold gated technique
in IMRT, it can further improve the target coverage and
reduction of doses to the heart, lung, and LAD. SIB tech-
nique could reduce the overall treatment duration by about
one week.
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